印度多重耐药病原体的死亡负担:一项回顾性观察研究
该研究在印度10家医院回顾性分析5103份药敏试验结果,评估多重耐药病原体与患者死亡的关系。总体死亡率为13.1%(n=581),多重耐药与死亡显著相关。多重耐药和广泛耐药大肠埃希菌、广泛耐药肺炎克雷伯菌及多重耐药鲍曼不动杆菌感染与2-3倍死亡率升高相关。
要点
- 多重耐药与死亡显著相关,总体死亡率13.1%。
- XDR大肠埃希菌、XDR肺炎克雷伯菌及MDR鲍曼不动杆菌感染死亡风险高2-3倍。
- MRSA对氨基糖苷类耐药时死亡率显著高于敏感菌株。
核心结论
- 多重耐药细菌感染对患者构成显著风险,且不同病原体的耐药与死亡关联有别于高收入国家。
研究设计与样本
- 回顾性、10家医院的观察性研究,分析5103份药敏试验结果与患者死亡结局的关联。
主要发现
- 患者总体死亡率为13.1%(n=581)。
- MDR和XDR大肠埃希菌、XDR肺炎克雷伯菌及MDR鲍曼不动杆菌感染与2-3倍死亡率升高相关。
- MRSA对氨基糖苷类耐药时死亡率显著高于敏感菌株。
临床怎么用
- 在低收入和中等收入国家应关注MDR/XDR大肠埃希菌、肺炎克雷伯菌和鲍曼不动杆菌感染的死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The threat posed by antibiotic resistance is of increasing concern in low- and middle-income countries (LMICs) as their rates of antibiotic use increase. However, an understanding of the burden of resistance is lacking in LMICs, particularly for multidrug-resistant (MDR) pathogens. METHODS: We conducted a retrospective, 10-hospital study of the relationship between MDR pathogens and mortality in India. Patient-level antimicrobial susceptibility test (AST) results for Enterococcus spp., Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. were analyzed for their association with patient mortality outcomes. RESULTS: We analyzed data on 5103 AST results from 10 hospitals. The overall mortality rate of patients was 13.1% (n = 581), and there was a significant relationship between MDR and mortality. Infections with MDR and extensively drug resistant (XDR) E. coli, XDR K. pneumoniae, and MDR A. baumannii were associated with 2-3 times higher mortality. Mortality due to methicillin-resistant S. aureus (MRSA) was significantly higher than susceptible strains when the MRSA isolate was resistant to aminoglycosides. CONCLUSIONS: This is one of the largest studies undertaken in an LMIC to measure the burden of antibiotic resistance. We found that MDR bacterial infections pose a significant risk to patients. While consistent with prior studies, the variations in drug resistance and associated mortality outcomes by pathogen are different from those observed in high-income countries and provide a baseline for studies in other LMICs. Future research should aim to elucidate the burden of resistance and the differential transmission mechanisms that drive this public health crisis.
引用
- Gandra S, Tseng KK, Arora A, et al. The Mortality Burden of Multidrug-resistant Pathogens in India: A Retrospective, Observational Study. Clin Infect Dis. 2019. PMID: 30407501. doi:10.1093/cid/ciy955
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。